María Jesús Rubio

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse et al. · The Lancet Oncology · 2020 · 433 citations

Second-line Treatment, Oncology, Metronomic Therapy +9

Radical surgery‐peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer

Sebastián Rufián, Francisco Cristobal Muñoz‐Casares, Javier Briceño et al. · Journal of Surgical Oncology · 2006 · 120 citations · Full text

LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial

Mansoor Raza Mirza, Line Bjørge, Frederik Marmé et al. · Annals of Oncology · 2020 · 81 citations

Endocrine-related Cancer, Medicine, Pharmacology +8

The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer

Francisco Cristobal Muñoz‐Casares, Sebastián Rufián, María Jesús Rubio et al. · Clinical & Translational Oncology · 2009 · 68 citations

Surgical Oncology, Gynecological Surgery, Peritoneal Carcinomatosis +10

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

Christian Marth, R. Tarnawski, Alexandra Tyulyandina et al. · International Journal of Gynecological Cancer · 2021 · 63 citations · Full text